Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Daraxonrasib + Gemcitabine + Nab-paclitaxel + Zoldonrasib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Daraxonrasib | Rasonque | RMC 6236|RMC6236|RMC-6236 | RAS Inhibitor (Pan) 17 | Rasonque (daraxonrasib) forms a binary complex with CypA, which prevents GTP-bound RAS from interacting with downstream effectors, potentially leading to anti-tumor activity (Cancer Res 2022;82(12_Suppl): Abstract nr 3597, PMID: 38593348). Rasonque (daraxonrasib) is FDA-approved for use in patients with metastatic pancreatic adenocarcinoma (FDA.gov). |
| Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
| Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
| Zoldonrasib | RMC 9805|RMC9805|RMC-9805|RM036|RM-036|RM 036 | KRAS G12D Inhibitor 26 | Zoldonrasib (RMC-9805) inhibits KRAS G12D, which potentially results in reduced downstream signaling and proliferation, induction of apoptosis, and decreased tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 526). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|